Form 4: DarioHealth CEO Receives Stock Grant
Insider Transaction (Form 4)
Erez Raphael, Chief Executive Officer and a Director of DarioHealth Corp., reported multiple transactions in common stock on August 12, 2024.
Summary
- Conversion of derivative: acquired 579 Common Stock at $19.10 ($11,059) on August 12, 2024; holds 157,432 after (Direct).
- Grant/award: acquired 297,000 Common Stock on September 24, 2026; holds 454,432 after (Direct).
- Conversion of derivative: disposed of 30 Series B-2 Preferred Stock at $1,000.00 ($30,000) on August 12, 2024 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Erez Raphael — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2024-08-12 | Conversion of derivative | Common Stock | 579 | $19 | $11.1K | 157,432 |
| 2026-09-24 | Grant/award | Common Stock | 297,000 | — | — | 454,432 |
| 2024-08-12 | Conversion of derivative | Series B-2 Preferred Stock | 30 | $1.0K | $30.0K | 0 |
Key Dates
| Date | Description |
|---|---|
| 2024-08-12 | Conversion of derivative (579 shares) |
| 2026-09-24 | Grant/award (297,000 shares) |
| 2024-08-12 | Conversion of derivative (30 shares) |
Keywords
insider transaction, Form 4, DRIO, DarioHealth Corp., neutral, Erez Raphael
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.